Studies related to Endothelin-1 and Pycnogenol

Reduction Of Cardiovascular Risk Factors In Subjects With Type 2 Diabetes By Pycnogenol Supplementation

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 45
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
Supplementation of 125mg pycnogenol daily for 12 weeks in type II diabetics currently on ACE inhibitor therapy showed benefits to blood pressure in 58.3% of subjects by halving their required dosage of ACE inhibitor. Other biomarkers, such as endothelin-1, glucose, and HbA1c all decreased relative to placebo.

A reduction in urinary albumin was noted after two months but this may have reached significance due to a spike in the placebo group, both groups normalized within three months of supplementation and there was no significant differences at this time.

Most effects required two months of supplementation to manifest, maintaining in potency for the third month and not occurring within the first.
Funding issues for this study:
Study funded by Horphag research, producers of pycnogenol supplements

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.